TURKISH JOURNAL of ONCOLOGY Turk J Oncol 2019;34(Supp 1):1–10

doi: 10.5505/tjo.2019.1

History of Brachytherapy

Gönül KEMİKLER
Department of Medical Physics, İstanbul University Institute of Oncology, İstanbul-Turkey

SUMMARY
The origin of brachytherapy is directly related to the discovery of radioactivity by Becquerel in 1896, which
led to Marie and Pierre Curie discovering radium in 1898. The first successful radium brachytherapy was
the skin irradiation of two patients with basal cell carcinoma in St. Petersburg in 1903. The surface mold
and plaque treatments were followed by intracavitary techniques for cervical and endometrial cancer.
A few years later, an interstitial radium brachytherapy technique was developed, and most body areas
were treated with radium brachytherapy. In the 1950s, radium was replaced by artificial cobalt-60 and
cesium-137. In the 1960s, iridium-192 was the most commonly used source of brachytherapy. During
this time period, remote afterloading devices were developed, and improvements in imaging techniques
and computer technology were adapted to brachytherapy. The evolution of brachytherapy has continued
over the years, but many of the techniques have remained unchanged. The limited use of brachytherapy
compared to conformal external radiotherapy may be due to its invasive approach, operative risk, tech-
nical difficulty, and long learning curve. Today with the development of imaging techniques and dose
planning, individual treatment planning has become possible. The success of brachytherapy has increased
with extensive technological advances, accurate three-dimensional dose distributions in the patient, and
optimization of treatment planning. In this article, the history of brachytherapy will be briefly reviewed.
Keywords: Brachytherapy history; dosimetry systems; iridium; radioactivity; radium.
*Emeritus professor
Copyright © 2019, Turkish Society for Radiation Oncology

Brachytherapy is a treatment modality as old as the his- discovered that uranium spontaneously emitted rays
tory of radiotherapy in cancer treatment.[1] The word similar to Roentgen rays.
brachytherapy is derived from the word brachy, which He identified natural radioactivity in his photo-
means “short” in Greek. In brachytherapy, closed ra- graphic album in contact with uranium crystals in
dioactive sources are placed in or near the tumor. In 1896. In 1898, Marie Sklodowska Curie and her hus-
many ways, brachytherapy can be considered the fi- band, Pierre Curie (Fig. 2), first identified polonium
nal form of conformal radiation therapy because it is and radium, two radioactive elements present in
unique in its ability to deliver high amounts of radia- minute quantities in uranium ore.
tion to the tumor, while minimizing radiation exposure Shortly after the discovery of radioactivity, Pierre
to normal structures. Brachytherapy has a long history Curie recommended the use of radioactive isotopes
in the treatment of neoplastic disease. The history of for cancer treatment. At the same time, Alexander
brachytherapy began in 1896 in Paris. Following the Graham Bell made a similar proposal in the United
discovery of X-rays by Wilhelm Konrad von Röentgen States. Thus, these rays were used in medicine in the
in 1895, French physicist A. Henri Becquerel (Fig. 1) early 1900s.

Dr. Gönül KEMİKLER

İstanbul Üniversitesi Onkoloji Enstitüsü,
Tıbbi Fizik Anabilim Dalı,
İstanbul-Turkey
E-mail: [email protected]
2 Turk J Oncol 2019;34(Supp 1):1–10
doi: 10.5505/tjo.2019.1

a b mor, he placed radium capsules previously implanted

in celluloid tubes into the tumor bed. Thus, he pio-
neered the afterloading technique of radium treatment
in the United States.
On 19 April 1906, Pierre Curie died in a tragic street
accident. His death was a turning point in both Marie’s
personal life and career, because she had to bring up
her two daughters. However, she did not give up and
continued their common work.
In 1906, Danne, Dominici, Degrais, and Wickham
established the first “Radium Biological Laboratory” in
Paris. In 1909, Finze started treating patients with ra-
dium in England. Treatment of prostatic disease with
Fig. 1. (a) Wilhelm K Röentgen, (b) Henri Becquerel.
radium was first reported in Paris, at a meeting of the
Assoçiation Françoise d’Urologie in October 1909.[4]
Henri Minet treated cancers of the prostate, bladder,
and ureter with a silver tube containing 10 mg of ra-
dium, applied through a urethral catheter or a supra-
pubic cystotomy.[5]
Urologist Octave Pasteau and radium therapist
Paul-Marie Degrais also began treating prostate cancer
with intracavitary radium in 1909, but their first reports
did not appear for several years.[6] Pasteau’s rationale
for preferring brachytherapy to prostatectomy was that
“in cancer of the prostate the curative treatment by op-
eration is in truth illusory; it is dangerous, and gives
Fig. 2. Marie Sklodowska Curie and Pierre Curie.
the most temporary results,” whereas these tumors are
“particularly susceptible to the influence of radium.”[7]
Initially, radium sources were formed with superfi- They had used a silver capsule, containing 10 to
cial applicators. Henri Becquerel and Pierre Curie ob- 50 mg of radium sulfate, placed near the tip of a 17 Fr
served the biological effects of radium on the skin. In coudé urinary catheter. Five treatment sessions, each
1901, Marie and her husband Pierre Curie had loaned a lasting 2 to 3 hours, were delivered over 2 weeks. The
small radium tube containing 0.398 g of radium sulfate series could be repeated periodically (annual mainte-
to Alexandre Danlos and Paul Bloch at St. Louis Hospi- nance treatments were prescribed for patients who had
tal in Paris, who treated a patient with lupus and then enjoyed a complete response). The first radium therapy
the treatment of malignant tumors by brachytherapy book was published by Wickham and Degrais in 1909
was started.[2] and was translated into English soon.[8]
Radium rays were soon found to have biological In 1909, Marie founded the Institute of Radium in
properties similar to those of X-rays. In 1903, Bec- Paris, which was designed to study radioactivity and
querel, together with Marie and Pierre Curie, received the biological effects of ionizing radiation. For that
the Nobel Prize for Physics for their discovery of ra- purpose, the Institute was divided into two laborato-
dioactivity. In the same year, the treatment of radium ries: the Curie Pavilion, directed by Marie Curie, and
in gynecological malignancies was reported for the the Pasteur Pavilion, directed by Claudius Regaud, a
first time. professor of histology and pathology.
In 1903, the first gynecological brachytherapy was After death of Pierre Curie, Marie Curie continued
described by Margareth A. Cleaves in New York. Pa- her research. The Nobel Prize in Chemistry 1911 was
tient with inoperable cervix uteri cancer was treated awarded to Marie Curie, “in recognition of her services
with 700 mg radium bromide put into the glass tube. to the advancement of chemistry by the discovery of
[3] In New York, Robert Abbe from St. Luke Memorial the elements radium and polonium, by the isolation of
Hospital performed the first radium implant following radium and the study of the nature and compounds of
the excision of tumor in 1905. After removing the tu- this remarkable element.”
Kemikler 3
Brachytherapy History

With the discovery of the radium isotope, clinical established at Memorial Hospital in 1915 with Henry
trials and experiments have increased rapidly. Curie is H. Juneway, a surgeon. Beginning in 1915, Memorial’s
defined as the activity unit of a nuclear decay rate of urologist, Benjamin Barringer, used these needles for
1 g radium. After 1950s, the dose calculations of the outpatient treatment of prostate cancer.[13] The nee-
obtained radioisotopes and the dose calculations in the dle, bearing 50–100 mCi of radon in its distal 3 cm,
brachytherapy applications were based on the mg-ra- was left in place for 4 to 6 hours before being retracted
dium equivalent (mgRaEq). and inserted into the other lateral lobe. Barringer re-
Although pitchblende ore is almost 50% uranium, ported highly favorable tumor responses. At first,
radium makes up only about one part per million. Tons “bare” glass tubes were implanted into tumors, but
of uranium ore were processed to obtain a single gram this practice resulted in painful sloughing of necrotic
of radium. James Douglas, a Canadian–American tissue. Memorial’s physicist, Gioacchino Failla, recog-
mining engineer, and surgeon Howard Kelly (Amer- nized the offender to be unfiltered caustic beta parti-
ica’s leading gynecologist) established the “National cles. He remedied the problem by encasing the radon
Radium Institute” in cooperation with the Office of the in a 0.3-mm-thick envelope of gold that filtered out
United States Bureau in 1913. A total of 8.5 grams of 99% of beta particles, while allowing > 80% of thera-
radium were refined until 1917. One-half gram was do- peutic gamma rays to pass.[14] Barringer implanted up
nated to government hospitals, and the remaining ra- to 20 seeds, each containing 1.5 to 2.0 mCi of radon,
dium was divided between Kelly and Douglas. Douglas into the prostate, typically delivering 4.000 mCi h of
donated his 4 g to New York’s Memorial Hospital, with treatment.[15] Barringer’s techniques were adopted at
the stipulation that the hospital become dedicated to other institutions [16,17], and a “gold” radon seed in-
the treatment of cancer.[9] dustry was established, which persisted in the United
Radium’s specific activity (ratio of activity to mass) States for decades.[18]
is low, due to its long half-life (1.600 years). In practi- After the First World War, radium treatment of
cal terms, it takes at least a week to deliver a curative carcinoma of the cervix was started by Gösta Forssell
dose with radium needles. This would be particularly in 1910 when Radiumhemmet (the Radium House)
awkward for the treatment of prostate cancer, as the was established in Stockholm. In 1914, the radiother-
sources would be left in an open suprapubic or per- apy department was divided into a gynecology sec-
ineal wound for an extended period.[10] The solution tion under James Heyman and a general section. The
to this problem lies in radon, radium’s first daughter brachytherapy method for treatment of cervix carci-
product. Radon has a very high specific activity, owing noma is usually referred to “the Stockholm technique”
to its short (3.8 day) half-life; despite being a gas, 1 Ci and the method for the treatment of uterus carcinoma
of radon has a volume of less than 1 mm3. Because of as the “Heyman packing technique.” At the same time,
its high specific activity, an “emanation” needle could the Memorial Hospital in New York and Institut du
be much thinner than a radium needle. Consequently, Radium/Curie Institute in Paris were established. In
radium salts were kept in an aqueous solution, and the these centers, dosimetry systems have been developed
emitted radon gas was harvested for therapeutic ap- for two- dimensional (2D) dose distributions and point
plications. Unfortunately, the collected gas was mostly dose calculations before the computer age. Methods
composed of water vapor, hydrogen, and oxygen. Har- of intracavitary brachytherapy were described by the
vard biophysicist William Duane had spent 7 years as schools of Stockholm and Paris in 1914 and 1919, re-
a research associate of the Curies, much of that time spectively. In the 1920s, Edith H. Quimby calculated
focusing on the purification of radon. On his return to the erythema-producing exposure dose in terms of
the United States, he built a radium emanation plant at “mg Ra h” at the New York.[19]
Boston’s Collis P. Huntington Hospital, which he repli- In the 1920, the interest and contributions to radi-
cated at Memorial Hospital.[11,12] ology increased; Sievert in Sweden, Mayneord in Eng-
Memorial’s entire 4 g of radium was kept in solu- land and Dessauer in Germany established their lab-
tion, and the purified radon was encapsulated in short oratories. In the 1930s, the historical dosage systems
lengths of glass capillary tubes, 0.3 mm in diameters, were developed when computer treatment planning
which were inserted into hypodermic needles. The and dose computations were not available. The Quimby
radon-bearing needles were used for temporary im- system by E. Quimby in New York and the Paterson–
plantation (the needles’ steel filtered most beta parti- Parker calculation system by Ralston Paterson and
cles and soft gamma rays). A radium department was Herbert Parker in Manchester were developed for in-
4 Turk J Oncol 2019;34(Supp 1):1–10
doi: 10.5505/tjo.2019.1

tracavitary brachytherapy.[20-22] Paterson, Tod, and istry 1935 was awarded jointly to Frédéric Joliot and Irène
Meredith introduced two arbitrary points, A and B, to Joliot-Curie “in recognition of their synthesis of new ra-
integrate x-ray doses given from outside, with gamma dioactive elements.” In the decade after World War II,
doses administered internally. Then, the rules of inter- radioisotopes such as cobalt-60 (Co-60), gold-198 (Au-
stitial radium treatment were published by Meredith as 198), tantalum-182 (Ta-182), and cesium-137(Cs-137)
Manchester system.[23] were introduced and became the radionuclides of choice
Ernest Rutherford’s discovery of artificial radioac- in intracavitary therapy, replacing radium-226. In 1958,
tivity (a winner of the Nobel Prize in Chemistry in iridium-192 (Ir-192), which replaced these sources, was
1908) in 1919 became the source of significant break- first used clinically by Ulrich Henschke at the Memorial
through in diagnosis and treatment in physics and Sloan Kettering Cancer Center.[24]
medicine. After the very first discoveries made by In 1960, Henschke described an afterloading tech-
Ernest Rutherford, Pierre and Marie Curie’s daugh- nique for tumors of the uterus and cervix, which re-
ter, Irène Joliot-Curie, and her husband, Frédéric Jo- duced exposure to staff. He inserted empty containers
liot (Fig. 3), a new point of view was developed. They in the operating room and later in the ward inserted
discovered that the point of view that although atoms radioactive sources via connecting tubes.
appear to be stable, they can be transformed into new In 1935, Prof. Dr. Friedrich Dessauer founded The
atoms with different chemical properties. In 1934, Radiology and Biophysics Institute of Istanbul Univer-
Irène Curie and Frederick Joliot discovered artificial sity (today’s Istanbul University Oncology Institute)
radionuclides and opened the possibility of a new era (Fig. 4), which was one of the most advanced institutes
of brachytherapy using artificial radionuclides. of the time with regard to technical equipment.
Today, over one thousand artificially created radioac- Brachytherapy had been started in Turkey with this
tive nuclides exist, which considerably outnumber the Institute using radium needle and tubes. Dessauer had
non-radioactive ones created. The Nobel Prize in Chem- brought 100 mg radium with him when coming to
Turkey.[25] In a short time, the radium capacity was
increased to 200 mg for intracavitary and interstitial
applications.
In 1952, The MD Anderson technique was pre-
sented by Gilbert Fletcher. The Fletcher applicator,
which is the most widely used vaginal colpostate in the
United States, was identified in 1953.[26]
Prof. Dr. Reha Uzel who worked with Ulrich
Henschke and pioneered gynecological tumors and
brachytherapy in Turkey was the first to perform the
intracavitary application with Manchester type rubber
ovoid and intrauterine applicators in 1955 with Seyfet-
tin Kuter (the pioneer of medical physics in Turkey)
(Fig. 5). He applied Au-198 seeds and Ta-182 hairpins
to various tumors at Radiotherapy Department of Is-
tanbul Medical Faculty. Figure 6 shows the brachyther-
apy applications in Radiology Institute, radiotherapy
department in 1955.[27]
In 1957, eye tumors were treated with stron-
siyum-90 (Sr-90) eye applicators. Applicators are cur-
rently used in the clinic.
The occupational concern related to the harmful ef-
fects of radium exposure in the second half of the 20th
century, technical advances in external beam treatment,
advances in imaging and surgical methods have led to a
decrease in the interest in brachytherapy and a signifi-
cant decrease in its use. However, the discovery of man-
Fig. 3. Irene and Frederic Joliot-Curie.
made radioisotopes and remote afterloading techniques
Kemikler 5
Brachytherapy History

a b

Fig. 4. (a)Prof. Dr. Friedrich Dessauer, German physicist, (b)The Radiology and Biophysics Institute, Çapa (1935).

a b devices were built in the Çapa and Cerrahpaşa Radi-

ation Oncology department of Istanbul University.
As a result of developing technologies, many HDR
brachytherapy devices have been used especially in in-
tracavitary brachytherapy.
In the 1970s, the dosimetry rules of the Paris system
were determined by Chassagne, Pierquin, and Dutreix
(Fig. 7) in interstitial treatment.[29-31]
By means of these rules, radioactive Ir-192 wires
could be loaded to be manually afterloading to sur-
Fig. 5. (a) Prof. Dr. Reha Uzel, (b) Assoc. Prof. Dr. Sey- gically implanted empty tubes by 2D imaging meth-
fettin Kuter. ods. In the 1980s, new brachytherapy approaches to
the treatment of prostate cancer were initiated.[32]
and subsequent reduction of the risk of exposure to radi- Martinez and colleagues [33] treated patients with
ation has renewed interest in brachytherapy. EBRT combined with temporary seeds inserted using
a transperineal approach. Dr Puthawala and colleagues
In the 1960s, Drs Scardino and Carlton [28] at Bay-
[34] pioneered a temporary seed technique of placing
lor College of Medicine in Houston, TX, started to per-
the needles, while visualizing them through an open
form permanent prostate brachytherapy alone or with
laparotomy. At about the same time, Dr Whitmore and
external beam radiation therapy using Au-198 intersti-
colleagues [35] at Memorial Sloan Kettering Cancer
tial implantation or iodine-125 (I-125).
Center also began to insert I-125 seeds as a sole treat-
In 1969, the Co-60 remote controlled Cathetron ment through an open incision. Significant limitations,
device was established at the radiotherapy department such as the requirement for an open incision, dosime-
(Çapa) at Istanbul Faculty of Medicine. Thus, the high- try issues, and poor outcomes, prevented the adoption
dose-rate (HDR) brachytherapy was started. In 1973, of these techniques. Lack of prostate-specific antigen
Dr. Gökhan Töre, a gynecologist, started working as an screening (for ideal patient selection) also contributed
assistant at the same department and predominantly to high recurrence rates. However, some important in-
head toward to gynecological oncology. formation was obtained from these early seed implan-
Following the transfer of Dr. Uzel to Radiation On- tation approaches. Local control was better in patients
cology of Cerrahpaşa Medical Faculty in 1978, he con- who received high-quality implants and who had low-
tributed greatly to the development of gynecological grade and early-stage cancer.[36-38]
oncology and brachytherapy. In 1979, Curietron HDR These results suggested that quality seed placement
Co-60 and low-dose-rate (LDR) Cs-137 brachytherapy and proper patient selection were important determi-
6 Turk J Oncol 2019;34(Supp 1):1–10
doi: 10.5505/tjo.2019.1

a b c

Fig. 6. (a) Surface treatment with Ra-226 tubes in cancer treatment, (b) interstitial brachytherapy with Ra-226 needles,
(c) treatment with the Au-198 seeds.

a b c

Fig. 7. (a) Daniel Chassagne, (b) Bernard Pierquin, (c) Andrée Dutreix.

nants of cancer control. The subsequent development permanent seed implantation. In 1983, Hans Henrik
of the transperineal, ultrasound-guided approach pro- Holm [39] introduced the use of transrectal ultrasound
vided a theoretical means to more accurately place to visualize the permanent placement of I-125 seeds via
seeds and to improve dose coverage. needles inserted through the perineum directly into the
The use of low-energy photon sources such as I-125, prostate. He was implanting I-125 seeds into cancerous
Pd-103 and Cs-131 with permanent implant technique prostates, under the direction of axial imaging from
has been widely used in the treatment of prostate can- a rectal probe mounted on a sledge-stepper (stepping
cer since the 1980s. Since the mid-1980s, the transrec- unit). Preplanning and implantation were performed
tal ultrasound-guided, template-guided I-125 implan- with the patient in the lithotomy position. In 1985,
tation procedure has become the primary technique of Blasko and Ragde [40] began the first transperineal,
Kemikler 7
Brachytherapy History

a b brachytherapy that it allowed computerized treatment

planning of the implant rather than the use of sim-
ple nomograms, thus ensuring the proper number,
strength, and positioning of radioactive sources. Per-
manent seed implantation has subsequently evolved
over the past 19 years to become an efficient procedure,
suitable for outpatient and ambulatory surgical centers.
c In the 1990s, interstitial applications were started
with low-dose Ir-192 wires in the Department of Ra-
diotherapy (Çapa) in the Istanbul Medical Faculty of
Istanbul University. With the introduction of Ir-192
into brachytherapy, radium sources have been replaced
by this new source for intracavitary and interstitial
therapy. The LDR intracavitary afterloading applica-
tions were continued with tandem ovoid applicator
Fig. 8. (a) Prof. Dr. Gökhan Töre, (b)T+O applicator for
uterus and cervix, (c) ans applicator for vaginal and an applicator developed by Töre [41] for the cervix
vault. and vaginal vault irradiation (Fig. 8).
Since 2000, permanent prostate brachytherapy
ultrasound-guided approach in the United States. The (Fig. 9) has been performed under the guidance of
transperineal, ultrasound-guided approach resulted transperineal ultrasound with LDR I-125 sources at
in increased accuracy of needle and seed placement the Oncology Institute of Istanbul. At the same time,
and relatively even distribution of seeds throughout plaque brachytherapy (Fig. 10) was initiated with I-125
the prostate. It marked a major advance in prostate sources for the treatment of uveal melanoma.

a b c

Fig. 9. Permanent prostate brachytherapy with LDR I-125 sources.

a b c

Fig. 10. Plaque brachytherapy with I-125 sources for the treatment of uveal melanoma.
8 Turk J Oncol 2019;34(Supp 1):1–10
doi: 10.5505/tjo.2019.1

In brachytherapy, the traditional approach based ture and protection of surrounding tissues from high
on two orthogonal radiographs taken after placement doses is a conformal treatment modality. As a result of
of applicators has a limited treatment planning opti- technical developments in imaging and computer soft-
mization capability. The optimization of cervical can- ware, IMRT (inverse planning) and adaptive planning
cer brachytherapy is aimed at providing an adequate techniques can be used in brachytherapy as in external
dose to Manchester A point by keeping the doses at radiotherapy. Even in curative treatment of cervical
the ICRU rectum and bladder points below the dose cancer, adaptive therapies have become a necessity in
limits.[42] some settlements. With the publication of ICRU 89,
Later, remote afterloading devices were further de- these treatments have been standardized worldwide.
veloped with the programable miniature high activity [48] Most of the devices in our country were established
moving source (stepping source). HDR treatments in the 2000s.[49] With the development of empirical
and pulsed-dose-rate (PDR) treatments replaced LDR 2D therapies and the development of software technol-
brachytherapy, except for LDR prostate permanent ogy from the beginning to the present, brachytherapy
brachytherapy and uveal melanoma brachytherapy. has evolved into 3D treatments and continues to un-
Newer imaging modalities [computed tomography dergo a change reflecting today’s technology. In a num-
(CT) scan, magnetic resonance imaging (MRI), tran- ber of radiotherapy centers, brachytherapy treatment
srectal ultrasound] and sophisticated computerized volumes can be determined in 3D by CT, MR, PET, or
treatment planning has helped to achieve increased ultrasound. It is expected that it is the wide introduc-
positional accuracy and superior, optimized dose dis- tion of modern imaging tools into the clinical practice.
tribution. New generation dose calculation algorithms supply
The local control rates of traditional brachyther- the tissue inhomogeneity corrections in planning
apy are approximately 80%–90% for small tumors, systems. With inverse planning, as with IMRT, dose
whereas the results for local advanced disease are optimization becomes the standard in CT treatment
suboptimal.[43] Cross-sectional imaging has been planning for many anatomical regions. Nevertheless,
implemented in the brachytherapy planning in many it is necessary to know that optimization cannot make
centers over the last decade. Optimization has been a good dose distribution from a bad implant. In all
the standard feature of brachytherapy systems by treatments, radiobiological factors should be con-
changing the dwell time. 3D image-guided adaptive sidered in combination of external radiotherapy and
brachytherapy provides a comprehensive assessment brachytherapy. Therefore, routine use of biological
of tumor size in the diagnosis and each brachyther- optimization in brachytherapy is one of the ongoing
apy fraction. GYN GEC ESTRO Working Group pub- studies. Joint databases for MC-based algorithms will
lished reports on volume concepts.[44,45] At present, form the backbone of the new generation of commer-
MRI is preferred for the clinical and radiological cial treatment planning systems, in a combination
primary tumor spread in brachytherapy and the un- with a new validation prerequisite for those new al-
derstanding of the topography during brachytherapy. gorithms. Dose-to-water standards for brachytherapy
Compared with traditional brachytherapy, the dosi- source calibration become available with a better or at
metric advantages of this approach have increased least similar uncertainty level.
uncomplicated cure rates.[46,47] In contrast to lim- As a result, brachytherapy, with its 120-years-
ited 2D brachytherapy applications in well-defined long history, preserved its importance. It is clear that
geometric settings (gynecology, breast, and skin), ad- brachytherapy is the optimal way of delivering confor-
vances in imaging techniques, increased knowledge of mal radiotherapy tailored to the shape of the tumor,
radiation administration, and dosimetry have made while sparing the surrounding normal tissue. With the
possible the 3D treatment of complex tumor sites. The development of application techniques and technol-
development of HDR and the use of MR devices and ogy, its effectiveness increased further. Today, with the
the inclusion of PET-CTs have brought new dimen- development of imaging techniques, individual dose
sions to brachytherapy. After the superiority of MRI planning has become possible with the development
in determining the tumor volume in brachytherapy of CT and MRI. The success of brachytherapy has in-
was demonstrated, MR-compatible applicators have creased with extensive technological advances and ul-
been widely used in clinics. timately the ability to produce very accurate 3D radia-
Brachytherapy, because of its features such as indi- tion dose distributions in the patient and optimization
viduality, conformity to tumor, and anatomical struc- of brachytherapy planning.
Kemikler 9
Brachytherapy History

References 19. Quimby EH. The development of dosimetry in ra-

dium therapy. In: Hilaris BS, ed. Afterloading: 20
1. Brucer M. Brachytherapy. Am J Roentgenol Radium years of experience, 1955-1975. Proceedings of the
Ther Nucl Med 1958;79(6):1080–90. 2nd International Symposium on Radiation Therapy.
2. Pierquin, B., Wilson, J.F., Chassagne, D. Modern New York: Memorial Sloan-Kettering Cancer Center;
brachytherapy. NY: Masson Publishing USA; 1987. p. 1975. p. 1–6.
25–42. 20. Quimby EH. The grouping of radium tubes in packs
3. Aronowitz JN, Aronowitz SV, Robison RF. Classics in and plaques to produce the desired distribution of radi-
brachytherapy: Margaret Cleaves introduces gyneco- ation. Am J Roentgenol and Rad. Ther 1932;27:18–39.
logic brachytherapy. Brachytherapy 2007;6(4):293–7. 21. Paterson R, Parker H. A dosage system for gamma ray
4. Aronowitz JN, Grimard DL, Robison R. Prece- therapy. 1934. Br J Radiol 1934;7(82):592–632.
dence for prostate brachytherapy. Brachytherapy 22. Paterson R, Parker HM. A dosage system for intersti-
2011;10(3):201–7. tial radium therapy. Br J Radiol 1938;11(124):252–66.
5. Minet H. Applications du radium aux tumeurs vesi- 23. Meredith WJ. Radium dosage: Manchester system.
cales, a l’hypertrophie et au cancer de la prostate, etc 2nd ed. Edinburg: Livingstone; 1967.
[Applications of radium to bladder tumors, prostatic 24. Henschke UK, Hılarıs BS, Mahan GD. Afterloading
hypertrophy and cancer, etc.]. Proc Verb Mem Assoc in interstitial and Intracavitary radiation therapy. Am J
Franc Urol 1909;13:629–46. Roentgenol Radium Ther Nucl Med 1963;90(8):386–95.
6. Pasteau O, Degrais. De l’emploi du radium dans le 25. Berkman AT. Engelli-engebeli uzun yıllar [In Turkish]
traitement des cancers de la prostate [The employ- [Long years of difficulties and obstructions]. Istanbul:
ment of radium in the treatment of prostate cancer]. J Selar Ofset 1987;174:153–4.
Urologie Med Chirur 1913;4:341–66. 26. Fletcher GH. Cervical radium applicators with screen-
7. Pasteau O, Degrais. The radium treatment of cancer of ing in the direction of bladder and rectum. Radiology
the prostate. Arch Roentgen Ray 1914;18:396–410. 1953;60(1):77–84.
8. Wickham L, Degrais P. Radiumtherapie. Bailliere. 27. 26. Kuter S. Türkiyede radyoloji biliminin kuruluş tar-
Paris; 1909. ihi. Türk Onkoloji Dergisi 2011;26 Ek 1:1–74.
9. Aronowitz JN, Robison R F. Howard Kelly estab- 28. Scardino P, Carlton C. Combined interstitial and ex-
lishes gynecologic brachytherapy in the United States. ternal irradiation for prostatic cancer. In: Javadpour
Brachytherapy 2010;9(2):178–184. N, editor. Principles and Management of Urologic
10. Cade S. Radium Treatment of Cancer. New York, NY: Cancer. Baltimore, MD: Williams & Wilkins; 1983. p.
William Wood; 1929. 392–408.
11. Failla G. The physics of radium. In: Clark JG, Norris 29. Chassagne D, Raynal M, Pierquin B. Technic of en-
CC, editors. Radium in Gynecology Philadelphia, PA: docurietherapy by iridium 192 with plastic tubes in
JB Lippincott; 1927. p. 63. the breast tumors. [Article in French]. J Radiol Elec-
12. Duane W. Methods of preparing and using radioac- trol Med Nucl 1963;44:269–71.
tive substances in the treatment of malignant dis- 30. Pierquin B, Chassagne D, Chahbazian CM, Wilson JF.
ease and of estimating suitable doses. Boston Med J Brachytherapy. W.H. Green, editor. St Louis, Missouri;
1917;177:787–99. 1978.
13. Barringer BS. The treatment by radium of carcinoma 31. Dutreix A, Marinello G, Pierquin B, Chassagne D,
of the prostate and bladder. JAMA 1916;67:1442–5. Houlard JP. Recent developments in the Paris System.
14. Failla G. The development of filtered radon implants. Part two: devices called “in triangles” (author’s transl).
Am J Roentgenol Radium Ther 1926;16:507–25. [Article in French]. J Radiol 1979;60(5):319–25.
15. Barringer BS. Treatment of tumors of the urinary blad- 32. Sylvester J, Blasko JC, Grimm P, Ragde H. Interstitial
der and prostate gland. In: Portmann UV, ed. Clinical implantation techniques in prostate cancer. J Surg On-
Therapeutic Radiology. New York, NY: Thomas Nel- col 1997;66(1):65–75.
son & Sons; 1950. p. 309–22. 33. Martinez A, Edmundson GK, Cox RS, Gunderson LL,
16. Bumpus HC. Carcinoma of the prostate: a clini- Howes AE. Combination of external beam irradiation
cal study of a thousand cases. Surg Gynecol Obstet. and multiple-site perineal applicator (MUPIT) for
1926;43:150–5. treatment of locally advanced or recurrent prostatic,
17. Watson EM. A study of carcinoma of the lower urinary anorectal, and gynecologic malignancies. Int J Radiat
tract. J Urologie Med Chirur 1933;29:545–57. Oncol Biol Phys 1985;11(2):391–8.
18. Lubenau JO. Unwanted radioactive sources in the 34. Puthawala A, Syed A, Tansey L. Temporary irid-
public domain: a historical perspective. Health Phys ium implant in the management of carcinoma of the
1999; 76(2 Suppl): S16–S22. prostate. Endocurie Hyper Oncol 1985;1:25–33.
10 Turk J Oncol 2019;34(Supp 1):1–10
doi: 10.5505/tjo.2019.1

35. Whitmore WF Jr, Hilaris B, Grabstald H. Retropubic Van Limbergen E, eds. The GEC ESTRO Handbook of
implantation to iodine 125 in the treatment of pro- Brachytherapy. European Society of Therapeutic Radi-
static cancer. J Urol 1972;108(6):918–20. ology and Oncology, Brussels; 2002:300–63.
36. DeLaney TF, Shipley WU, O’Leary MP, Biggs PJ, Prout 44. Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De
GR Jr. Preoperative irradiation, lymphadenectomy, Brabandere M, Dimopoulos J, et al; Gynaecological
and 125iodine implantation for patients with localized (GYN) GEC-ESTRO Working Group. Recommen-
carcinoma of the prostate. Int J Radiat Oncol Biol Phys dations from Gynaecological (GYN) GEC-ESTRO
1986;12(10):1779–85. Working Group (I): concepts and terms in 3D im-
37. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, An- age based 3D treatment planning in cervix cancer
derson LL, et al. The effect of local control on metastatic brachytherapy with emphasis on MRI assessment of
dissemination in carcinoma of the prostate: long-term GTV and CTV. Radiother Oncol 2005;74(3):235–45.
results in patients treated with 125I implantation. Int J 45. Pötter R, Haie-Meder C, Van Limbergen E, Barillot I,
Radiat Oncol Biol Phys 1991;21(3):537–47. De Brabandere M, Dimopoulos J, et al; GEC ESTRO
38. Kovács G, Galalae R, Loch T, Bertermann H, Kohr P, Working Group. Recommendations from gynaecolog-
Schneider R, et al. Prostate preservation by combined ical (GYN) GEC ESTRO working group (II): concepts
external beam and HDR brachytherapy in nodal neg- and terms in 3D image-based treatment planning in
ative prostate cancer. Strahlenther Onkol 1999;175 cervix cancer brachytherapy-3D dose volume parame-
Suppl 2:87–8. ters and aspects of 3D image-based anatomy, radiation
39. Holm HH, Juul N, Pedersen JF, Hansen H, Strøyer I. physics, radiobiology. Radiother Oncol 2006;78(1):67–
Transperineal 125iodine seed implantation in pro- 77.
static cancer guided by transrectal ultrasonography. J 46. Lindegaard JC, Tanderup K, Nielsen SK, Haack S,
Urol 1983;130(2):283–6. Gelineck J. MRI-guided 3D optimization signifi-
40. Blasko JC, Radge H, Schumacher D. Transperineal cantly improves DVH parameters of pulsed-dose-rate
percutaneous iodine-125 implantation for prostatic brachytherapy in locally advanced cervical cancer. Int
carcinoma using transrectal ultrasound and template J Radiat Oncol Biol Phys 2008;71(3):756–64.
guidance. Endocurie Hyper Oncol 1987;3:131–9. 47. Pötter R, Georg P, Dimopoulos JC, Grimm M, Berger
41. Töre G, Aslay I, Dinçer M, Kemikler G. A new iridium D, Nesvacil N, et al. Clinical outcome of protocol
applicator for vaginal vault irradiation. Eur J Gynaecol based image (MRI) guided adaptive brachyther-
Oncol 1994;15(3):241–4. apy combined with 3D conformal radiotherapy
42. D. Chassagne A. Dutreix P. Almond J. M. V. Burgers with or without chemotherapy in patients with lo-
M. Busch C. A. Joslin. International Commission on cally advanced cervical cancer. Radiother Oncol
Radiation Units and Measurements (ICRU). Dose and 2011;100(1):116–23.
volume specification for reporting intracavitary ther- 48. Prescribing, Recording, and Reporting Brachytherapy
apy in gynecology. ICRU Report 38. ICRU, Bethesda, for Cancer of the Cervix. J ICRU 2013;13(1-2):NP.
MD; 1985. 49. Kuter S, Çakır A. Survey of Radiation Oncology Cen-
43. Gerbaulet A, Pötter R, Haie-Meder C. Cervix cancer. ters, Equipment and Manpower. Türk Onkoloji Der-
In: Gerbaulet A, Pötter R, Mazeron JJ, Meertens H, gisi 2004;19(3):87–96.